Acadia Pharmaceuticals

是其中之一......

• Russell 3000.

Acadia Pharmaceuticals 是一家在股票代码 ACAD (US) 下上市的公司。

查看带有其 29 名主要高管的组织结构图

Acadia Pharmaceuticals 搜索最多的简介

• Stephen Davis, Chief Executive Officer and Director
• Laura Brege, Director
• Edmund Harrigan, Director

高管在Acadia Pharmaceuticals变化

• Doug Williamson, Executive Vice President and Head of Research and Development 请很快离开公司  (新闻发布的2023十一月22号).
• Albert Kildani已作为Senior Vice President, Investor Relations and Corporate Communications加入公司  (新闻发布的2023九月20号).
• Kevin Oliver已作为Senior Vice President and Chief Business Officer加入公司  (新闻发布的2023七月25号).

创建提醒
跟踪 Acadia Pharmaceuticals 的高管变动

Acadia Pharmaceuticals 拥有 1,863 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。

Popular M&A news in 药店

• Revolution Medicines 已收购 Eqrx (公布2023十一月10号).
• Cybin 已收购 Small Pharma (公布2023十月24号).
• Horizon Therapeutics and Amgen have announced they will merge  (公布2023十月10号)..

药店 行业的其他推荐联系人

• Dirk Rossmann 企业 Alice Schardt-Rossmann - Managing Director
• Ferring Pharmaceuticals 企业 Jean-Frédéric Paulsen - Executive Chairman of the Board
• Zoetis 企业 Kristin Peck - Chief Executive Officer and Director

了解更多有关药店行业的信息 >

Acadia Pharmaceuticals 的最新新闻稿

• Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin) - Acadia Pharmaceuticals
• Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer - Acadia Pharmaceuticals
• Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023 - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Acadia Pharmaceuticals
• View more press releases Close

关于 Acadia Pharmaceuticals 的社交媒体

• Acadia Pharmaceuticals 在 维基百科、谷歌新闻 和 雅虎财经
• Acadia Pharmaceuticals 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Stephen Davis

致电Acadia Pharmaceuticals，电话：+1 858...

查看组织结构图

Register to receive your alert

报告错误